Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis

European Journal of Immunology

Volumn 41, Issue 6, 2011, Pages 1696-1708

  Calderón Gómez, Elisabeth ^a,g   Lampropoulou, Vicky ^a   Shen, Ping ^a   Neves, Patricia ^a   Roch, Toralf ^a,h   Stervbo, Ulrik ^a   Rutz, Sascha ^a,b   Kühl, Anja A ^c   Heppner, Frank L ^c   Loddenkemper, Christoph ^c,i   Anderton, Stephen M ^d   Kanellopoulos, Jean M ^e   Charneau, Pierre ^f   Fillatreau, Simon ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b GENENTECH INC   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

^f INSTITUT PASTEUR   (France)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h INSTITUTE OF MATERIALS RESEARCH   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Autoimmunity; B cells; Cellular therapy; Gene therapy; Lentiviral vector

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; CD86 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 10; LENTIVIRUS VECTOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; DEMYELINATION; MOUSE; NEUROPROTECTION; NONHUMAN; PEPROGRAMMED QUIESCENT B CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION;

EID: 79957553099     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201041041     Document Type: Article

References (47)

1. Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R. S. and Bhan, A. K., Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002. 16: 219-230.
2. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. and Anderton, S. M., B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 2002. 3: 944-950.
3. Mauri, C., Gray, D., Mushtaq, N. and Londei, M., Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 2003. 197: 489-501.
4. Lampropoulou, V., Hoehlig, K., Roch, T., Neves, P., Calderon Gomez, E., Sweenie, C. H., Hao, Y. et al., TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 2008. 180: 4763-4773.
5. Skupsky, J., Su, Y., Lei, T. C. and Scott, D. W., Tolerance induction by gene transfer to lymphocytes. Curr. Gene Ther. 2007. 7: 369-380.
6. Chen, C. C., Rivera, A., Dougherty, J. P. and Ron, Y., Complete protection from relapsing experimental autoimmune encephalomyelitis induced by syngeneic B cells expressing the autoantigen. Blood 2004. 103: 4616-4618.
7. Schultze, J. L., Michalak, S., Seamon, M. J., Dranoff, G., Jung, K., Daley, J., Delgado, J. C. et al., CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 1997. 100: 2757-2765.
8. Ito, O., Harada, M., Takenoyama, M., Tamada, K., Li, T., Abe, K., Fujie, H. and Nomoto, K., Vaccination with activated B cells pulsed with tumor-lysates can induce tumor-specific CD4+T cells in vivo. Immunobiology 1998. 199: 133-147.
9. Anderton, S. M. and Fillatreau, S., Activated B cells in autoimmune diseases: the case for a regulatory role. Nat. Clin. Pract. Rheumatol. 2008. 4: 657-666.
10. Meyer-Bahlburg, A. and Rawlings, D. J., B cell autonomous TLR signaling and autoimmunity. Autoimmun. Rev. 2008. 7: 313-316.
11. Eynon, E. E. and Parker, D. C., Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med. 1992. 175: 131-138.
12. Frommer, F., Heinen, T. J., Wunderlich, F. T., Yogev, N., Buch, T., Roers, A., Bettelli, E. et al., Tolerance without clonal expansion: self-antigen-expressing B cells program self-reactive T cells for future deletion. J. Immunol. 2008. 181: 5748-5759.
13. Zambidis, E. T., Barth, R. K. and Scott, D. W., Both resting and activated B lymphocytes expressing engineered peptide-Ig molecules serve as highly efficient tolerogenic vehicles in immunocompetent adult recipients. J. Immunol. 1997. 158: 2174-2182.
14. Green, N. M., Laws, A., Kiefer, K., Busconi, L., Kim, Y. M., Brinkmann, M. M., Trail, E. H. et al., Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J. Immunol. 2009. 183: 1569-1576.
15. Sweenie, C. H., Mackenzie, K. J., Rone-Orugboh, A., Liu, M. and Anderton, S. M., Distinct T cell recognition of naturally processed and cryptic epitopes within the immunodominant 35-55 region of myelin oligodendrocyte glycoprotein. J. Neuroimmunol. 2007. 183: 7-16.
16. McGeachy, M. J., Stephens, L. A. and Anderton, S. M., Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+regulatory cells within the central nervous system. J. Immunol. 2005. 175: 3025-3032.
17. Venken, K., Hellings, N., Liblau, R. and Stinissen, P., Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 2010. 16: 58-68.
18. Frentsch, M., Arbach, O., Kirchhoff, D., Moewes, B., Worm, M., Rothe, M., Scheffold, A. and Thiel, A., Direct access to CD4+T cells specific for defined antigens according to CD154 expression. Nat. Med. 2005. 11: 1118-1124.
19. Kuchroo, V. K., Martin, C. A., Greer, J. M., Ju, S. T., Sobel, R. A. and Dorf, M. E., Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J. Immunol. 1993. 151: 4371-4382.
20. Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y. H., Wang, Y. et al., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005. 6: 1133-1141.
21. Mann, M. K., Maresz, K., Shriver, L. P., Tan, Y. and Dittel, B. N., B cell regulation of CD4+CD25+T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol. 2007. 178: 3447-3456.
22. Soukhareva, N., Jiang, Y. and Scott, D. W., Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol. 2006. 240: 41-46.
23. Almeida, A. R., Zaragoza, B. and Freitas, A. A., Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4+CD25+regulatory T cells is indexed to the number of IL-2-producing cells. J. Immunol. 2006. 177: 192-200.
24. Zambidis, E. T., Kurup, A. and Scott, D. W., Genetically transferred central and peripheral immune tolerance via retroviral-mediated expression of immunogenic epitopes in hematopoietic progenitors or peripheral B lymphocytes. Mol. Med. 1997. 3: 212-224.
25. Agarwal, R. K., Kang, Y., Zambidis, E., Scott, D. W., Chan, C. C. and Caspi, R. R., Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J. Clin. Invest. 2000. 106: 245-252.
26. Melo, M. E., Qian, J., El-Amine, M., Agarwal, R. K., Soukhareva, N., Kang, Y. and Scott, D. W., Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J. Immunol. 2002. 168: 4788-4795.
27. Xu, B. and Scott, D. W., A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin. Immunol. 2004. 111: 47-52.
28. Satpute, S. R., Soukhareva, N., Scott, D. W. and Moudgil, K. D., Mycobacterial Hsp65-IgG-expressing tolerogenic B cells confer protection against adjuvant-induced arthritis in Lewis rats. Arthritis Rheum. 2007. 56: 1490-1496.
29. Fuchs, E. J. and Matzinger, P., B cells turn off virgin but not memory T cells. Science 1992. 258: 1156-1159.
30. Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L. and Charneau, P., HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000. 101: 173-185.
31. Sirven, A., Pflumio, F., Zennou, V., Titeux, M., Vainchenker, W., Coulombel, L., Dubart-Kupperschmitt, A. and Charneau, P., The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000. 96: 4103-4110.
32. Frecha, C., Costa, C., Levy, C., Negre, D., Russell, S. J., Maisner, A., Salles, G. et al., Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 2009. 114: 3173-3180.
33. Nayak, S. and Herzog, R. W., Progress and prospects: immune responses to viral vectors. Gene Ther. 2010. 17: 295-304.
34. Breckpot, K., Escors, D., Arce, F., Lopes, L., Karwacz, K., Van Lint, S., Keyaerts, M. and Collins, M., HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J. Virol. 2010. 84: 5627-5636.
35. Lampropoulou, V., Calderon-Gomez, E., Roch, T., Neves, P., Shen, P., Stervbo, U., Boudinot, P. et al., Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol. Rev. 2010. 233: 146-161.
36. De Meyer, S. F., Vanhoorelbeke, K., Chuah, M. K., Pareyn, I., Gillijns, V., Hebbel, R. P., Collen, D. et al., Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood 2006. 107: 4728-4736.
37. El-Amine, M., Melo, M., Kang, Y., Nguyen, H., Qian, J. and Scott, D. W., Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J. Immunol. 2000. 165: 5631-5636.
38. Ahangarani, R. R., Janssens, W., VanderElst, L., Carlier, V., VandenDriessche, T., Chuah, M., Weynand, B. et al., In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness. J. Immunol. 2009. 183: 8232-8243.
39. Viglietta, V., Baecher-Allan, C., Weiner, H. L. and Hafler, D. A., Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004. 199: 971-979.
40. Steinman, L., Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet]. J. Autoimmun. 2000. 14: 278-282.
41. Myhr, K. M. and Mellgren, S. I., Corticosteroids in the treatment of multiple sclerosis. Acta Neurol. Scand. Suppl. 2009: 73-80.
42. Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Gungor, T., Krackhardt, B. and Kornhuber, B., Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992. 339: 594-598.
43. Wang, J., Lozier, J., Johnson, G., Kirshner, S., Verthelyi, D., Pariser, A., Shores, E. and Rosenberg, A., Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat. Biotechnol. 2008. 26: 901-908.
44. Zaldumbide, A. and Hoeben, R. C., How not to be seen: immune-evasion strategies in gene therapy. Gene Ther. 2008. 15: 239-246.
45. Kohn, D. B., Update on gene therapy for immunodeficiencies. Clin. Immunol. 2010. 135: 247-254.
46. Sinn, P. L., Sauter, S. L. and McCrayJr, P. B., Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther. 2005. 12: 1089-1098.
47. Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L. et al., A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 2003. 33: 401-406.